The presence of superantigens and complex host responses in severe sepsis may need a broad therapeutic approach

Therapeutic Apheresis

Volumn 5, Issue 2, 2001, Pages 111-114

  Stegmayr, Bernd G ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apheresis; Bacteria; Multiorgan dysfunction syndrome; Plasma exchange; Septic shock; Superantigens; Therapy; Toxins

Indexed keywords

SUPERANTIGEN;

CLOSTRIDIUM; CONFERENCE PAPER; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; IMMUNE RESPONSE; MONOCYTE; MULTIPLE ORGAN FAILURE; NEISSERIA MENINGITIDIS; PLASMAPHERESIS; PLASMODIUM MALARIAE; PRIORITY JOURNAL; PSEUDOMONAS; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE ACTIVATION;

ANTI-BACTERIAL AGENTS; DIALYSIS; HUMANS; PLASMA EXCHANGE; RENAL DIALYSIS; SEPSIS; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SUPERANTIGENS; ULTRAFILTRATION;

EID: 0035023326     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2001.005002111.x     Document Type: Conference Paper

References (45)

1. Septic shock induced by group A streptococcal infection: Clinical and therapeutic aspects
2. Clinical and bacteriologic observations of a toxic shock-like syndrome due to streptococcus pyogenes
3. Plasma exchange in patients with acute renal failure in the course of multiorgan failure
4. Group A streptococcus invasive infections: A review
5. The gram-positive cocci. Group A streptococci
6. Superantigens of microbial origin
7. Interactions between staphylococcal superantigens and MHC class II molecules
8. B-cell superantigens: Molecular and cellular implications
9. B cell superantigens: Potential modifiers of the normal human B cell repertoire
10. Superantigens, T cells, and microbes
11. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma-interferon
12. Pathogenesis of disseminated intravascular coagulation in sepsis
13. STSS: Spectrum of disease, pathogenesis, and new concepts in treatment
14. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis
15. INTERSEPT: An international, multi-center, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis
16. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
17. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein
18. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial
19. Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis
20. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study
21. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial
22. Effect of pentoxifylline in severe sepsis: Results of a randomized, double-blind, placebo-controlled study
23. Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock
24. Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature
25. Adjunctive therapy with intravenous human immunoglobulin G improves survival of patients with acute renal failure
26. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants
27. Supplemental immune globulins in sepsis
28. Intravenous immunoglobulin therapy in streptococcal toxic shock syndrome: A comparative observational study
29. Structure and function of lipopolysaccharide binding protein
30. Increased plasma tumor necrosis factor concentration in severe rhabdomyolysis is not reduced by continuous arteriovenous hemodialysis
31. Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure
32. A novel acute-phase marker: Lipopolysaccharide binding protein (LBP)
33. Is cytokine removal by continuous hemofiltration feasible?
34. Cytokine removal during continuous hemofiltration in septic patients
35. Hemostatic alterations during continuous venovenous hemofiltration in acute renal failure
36. Influence of hematocrit on hemostasis in continuous venovenous hemofiltration during acute renal failure
37. Apheresis of plasma compounds as a therapeutic principle in severe sepsis and multiorgan dysfunction syndrome
38. On the use of liquid stored or cryoprecipitate-poor plasma in plasma exchange
39. Long-term study of the protein profiles in healthy volunteers after plasma exchange
40. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber
41. Therapeutic apheresis for septic patients with organ dysfunction: Hemoperfusion using a polymyxin B immobilized column
42. Correlation between plasma endotoxin, plasma cytokines and plasminogen activator inhibitor-1 activities in septic patients
43. Polymyxin-B stimulates tumor necrosis factor-alpha production by human peripheral blood mononuclear cells
44. Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome